Edible robots are here, and they might taste like gummy candy. Learn how these wiggly wonders could help in wildlife conservation.
Category: robotics/AI – Page 19
Chinese humanoid robot sets guinness world record with 106-km inter-city walk
New research shows that the magnetic part of light actively shapes how light interacts with matter, challenging a 180-year-old belief.
The team demonstrated that this magnetic component significantly contributes to the Faraday Effect, even accounting for up to 70% of the rotation in the infrared range. By proving that light can magnetically torque materials, the findings open unexpected pathways for advanced optical and magnetic technologies.
Revealing Light’s Hidden Magnetic Power
Dr. Carina Kern — CEO, LinkGevity — Necrosis Inhibitors To Pause The Diseases Of Aging
Necrosis Inhibitors To Pause The Diseases Of Aging — Dr. Carina Kern Ph.D. — CEO, LinkGevity
Dr. Carina Kern, Ph.D. is the CEO of LinkGevity (https://www.linkgevity.com/), an AI-powered biotech company driving innovation in drug discovery for aging and resilience loss.
Dr. Kern has developed a new Blueprint Theory of Aging, which takes an integrative approach to understanding aging, combining evolutionary theory, genetics, molecular mechanisms and medicine, and is used to structure LinkGevity’s AI.
Dr. Kern’s labs are based at the Babraham Research Campus, affiliated with the University of Cambridge and her research has led to the development of a first-in-class necrosis inhibitor targeting cellular degeneration (Anti-Necrotic™). This novel therapeutic is ready to begin Phase II clinical trials later this year, as a potential breakthrough treatment for aging, with UK Government, Francis Crick Institute KQ labs, and European Union (Horizon) support.
The Anti-Necrotic™ has also been selected as one of only 12 global innovations for NASA’s Space-Health program, recognizing its potential to mitigate accelerated aging in astronauts on long-duration space missions.
A new artificial muscle could let humanoid robots lift 4,400 times their weight
A new material bends that rule.
Researchers in South Korea say they have built a soft, magnetic artificial muscle that hits hard numbers without turning into a stiff piston. The material flexes, contracts and relaxes like flesh, yet ramps up stiffness on demand when asked to do real work. That mix has long sat out of reach for humanoid robots that need both agility and strength.
Most humanoids move with a cocktail of motors, gears and pneumatic lines. These systems deliver power, but they also add bulk and make contact risky. Soft actuators change the equation. They integrate into limbs, cushion impacts and tolerate misalignment. They also weigh far less than hydraulic stacks and slot neatly inside compact forms like hands, faces and torsos.
The cost of thinking: Reasoning models share aspects of information processing with human brains
Large language models (LLMs) like ChatGPT can write an essay or plan a menu almost instantly. But until recently, it was also easy to stump them. The models, which rely on language patterns to respond to users’ queries, often failed at math problems and were not good at complex reasoning. Suddenly, however, they’ve gotten a lot better at these things.
A new generation of LLMs known as reasoning models are being trained to solve complex problems. Like humans, they need some time to think through problems like these—and remarkably, scientists at MIT’s McGovern Institute for Brain Research have found that the kinds of problems that require the most processing from reasoning models are the very same problems that people need to take their time with.
In other words, they report in the journal PNAS, the “cost of thinking” for a reasoning model is similar to the cost of thinking for a human.
AI-Designed Proteins Can Boost Production of T Cells
Daley and Mout added that the team is excited that the approach can guide T cells to tumors, stimulate their cancer cell-killing abilities, and overcome immune suppression by the tumor microenvironment.
Mout, who trained in the lab of Nobel Prize-winning co-author and Rosetta creator David Baker, is especially enthusiastic about the technology’s far-reaching potential.
“Our goal is to develop next-generation immunotherapies and cancer vaccines,” he said.
Wireless image transmission technique filters redundant data intuitively—just like a human
A new AI-driven technology developed by researchers at UNIST promises to significantly reduce data transmission loads during image transfer, paving the way for advancements in autonomous vehicles, remote surgery and diagnostics, and real-time metaverse rendering—applications that demand rapid, large-scale visual data exchange without delay.
Led by Professor Sung Whan Yoon from the Graduate School of Artificial Intelligence at UNIST, the research team developed Task-Adaptive Semantic Communication, an innovative wireless image transmission method that selectively transmits only the most essential semantic information relevant to the specific task. Their study is published in the IEEE Journal on Selected Areas in Communications.
Current wireless image transmission methods compress entire images without considering their underlying semantic structures—such as objects, layout, and relationships—resulting in bandwidth limitations and transmission delays that hinder real-time high-resolution image sharing.
Immune checkpoint inhibitor-associated myocarditis and pericarditis: a pharmacovigilance study based on the FAERS database
Immune checkpoint inhibitors (ICIs) are medications used in cancer immunotherapy. However, treatment with ICIs may lead to adverse effects, particularly myocarditis and pericarditis. This practical pharmacovigilance study investigates the relationship between ICIs and myocarditis and pericarditis using the FAERS (U.S. FDA Adverse Event Reporting System) database.
Data on myocarditis and pericarditis related to ICIs were extracted from the FAERS database for the period from 2014Q1 to 2023Q4. Data mining was performed using the Bayesian Confidence Propagation Neural Network (BCPNN) and the Reporting Odds Ratio (ROR).
A total of 1,112 cases involving 1,134 adverse event (AE) reports related to ICIs-associated noninfectious myocarditis/pericarditis (NM/P) were extracted from the FAERS database. After excluding reports with missing data, the primary reporters were physicians, consumers, and pharmacists, with the United States and Japan being the main reporting countries. The cases showed a greater percentage of males than females, with a median age of 67 years, a median weight of 65 kg, and a median onset time of 28 days. The signal strength of ICIs-associated NM/P, from highest to lowest, was as follows: Pembrolizumab (ROR: 12.32, 95% CI: 11.28–13.45, IC 025: 3.45) Nivolumab (ROR: 11.23, 95% CI: 10.13–12.44, IC 025: 3.30) Atezolizumab (ROR: 10.62, 95% CI: 8.67–13.02, IC 025: 3.10) Ipilimumab (ROR: 10.25, 95% CI: 8.34–12.58, IC 025: 3.04) Durvalumab (ROR: 9.25, 95% CI: 7.21–11.88, IC 025: 2.83).